ArticleThe oncologist2024

Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study.

Michael H Storandt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.